Article
Co-occurring clonal hematopoiesis exhibits strong selection and high leukemia risk.
Nature communications - 21 May 2026
Barnao Kara M, Hubbard Aubrey K, Chan Irenaeus C C, Zhou Weiyin, Jakubek Yasminka A, Genovese Giulio, Wong Wendy S W, Kelly Rebecca L, Young Corey D, Brown Derek W, Huang Wen-Yi, Freedman Neal D, Jones Kristine, Hutchinson Amy, Hicks Belynda, Tran Duc, Arnett Donna, Barnes Kathleen C, Bis Joshua C, Boerwinkle Eric, Brody Jennifer A, Carson April P, Chasman Daniel I, Cho Michael H, Desai Pinkal, Doyle Margaret F, Fornage Myriam, Guo Xiuqing, Heard-Costa Nancy, Irvin Marguerite Ryan, Johnson Andrew D, Kardia Sharon L R, Kooperberg Charles, Levy Daniel, Lewis Joshua P, Li Yun, Loos Ruth J F, Mack Taralynn M, Mathias Rasika A, Mitchell Braxton D, North Kari E, Pankratz Nathan, Peyser Patricia A, Preuss Michael H, Psaty Bruce M, Raffield Laura M, Redline Susan, Rich Stephen S, Rotter Jerome I, Silverman Edwin K, Smith Albert V, Smith Jennifer A, Stilp Adrienne, Cao Yin, Scheet Paul, Reiner Alexander P, Bick Alexander G, Chanock Stephen J, Auer Paul L, Bolton Kelly L, Machiela Mitchell J
Abstract excerpt
Clonal hematopoiesis of indeterminate potential (CHIP) and mosaic chromosomal alterations (mCAs) are two types of clonal hematopoiesis (CH) associated with hematological parameters and malignancy risk. Here we show, in genomic data from 546,090 biobank participants, that co-occurring CH (≥2 CH mutations detected) is present in 1.6% of cancer-free individuals and shows strong evidence for selection (up to 804x...
Read the complete abstract on PubMed